Statin Therapy and Risk of Fracture: Results From the JUPITER Randomized Clinical Trial

This analysis of the JUPITER trialled showed that rosuvastatin did not reduce fracture risk in the enrolled patients with elevated hs-CRP levels.  Furthermore, higher baseline hs-CRP levels were nor associated with an increased risk of fractures in both groups. : Elevated Fibroblast Growth Factor 23 is a Risk Factor for Kidney Transplant Loss and Mortality The Pattern of Excess Cancer in Dialysis and Transplantation Vitamins C and E to Prevent Complications of Pregnancy-Associated Hypertension
Source: Nephrology Now - Category: Urology & Nephrology Authors: Tags: Clinical Nephrology Clinical Trial Results Source Type: research